Increased atherosclerosis and vascular smooth muscle cell activation in AIF-1 transgenic mice fed a high-fat diet

Atherosclerosis

Volumn 220, Issue 1, 2012, Pages 45-52

  Sommerville, Laura J ^a   Kelemen, Sheri E ^a   Ellison, Stephen P ^a   England, Ross N ^a   Autieri, Michael V ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Allograft inflammatory factor 1; Atherosclerosis; Nuclear factor kappa B; Oxidized LDL; Vascular smooth muscle cell

Indexed keywords

ALLOGRAFT INFLAMMATORY FACTOR 1; CD36 ANTIGEN; GELATINASE A; GELATINASE B; MESSENGER RNA; TRANSCRIPTION FACTOR RELA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CELL MIGRATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; HUMAN; HUMAN CELL; LIPID DIET; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SMOOTH MUSCLE FIBER; TRANSGENIC MOUSE; VASCULAR SMOOTH MUSCLE; WILD TYPE;

ANIMALS; ANTIGENS, CD36; AORTA, ABDOMINAL; AORTIC DISEASES; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CALCIUM-BINDING PROTEINS; CELL MOVEMENT; CELLS, CULTURED; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; HUMANS; LIPOPROTEINS, LDL; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MICROFILAMENT PROTEINS; MUSCLE PROTEINS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NF-KAPPA B; PROMOTER REGIONS, GENETIC; RNA, MESSENGER; TIME FACTORS; TRANSFECTION;

EID: 84155172773     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.07.095     Document Type: Article

References (30)

1. Doran A.C., Meller N., McNamara C.A. Role of smooth muscle cells in the initiation and early progression of atherosclerosis. Arterioscler Thromb Vasc Biol 2008, 5:812-819.
2. Pei H., Wang Y., Miyoshi T., et al. Direct evidence for a crucial role of the arterial wall in control of atherosclerosis susceptibility. Circulation 2006, 114:2382-2389.
3. Galis Z.S., Sukhova G.K., Lark M.W., Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994, 94:2493-2503.
4. Libby P. Inflammation in atherosclerosis. Nature 2002, 420:a868-a874.
5. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999, 340:115-126.
6. Raines E., Ferri N. Cytokines affecting endothelial and smooth muscle cells in vascular disease. J Lipid Res 2005, 46:1081-1092.
7. Singer C., Sonemany S., Baker K., Gerthoffer W. Synthesis of immune modulators by smooth muscles. BioEssays 2004, 26:646-655.
8. Chisolm G.M., Chai Y. Regulation of cell growth by oxidized LDL. Free Radic Biol Med 2000, 28:1697-1707.
9. Autieri M.V., Carbone C., Mu A. Expression of allograft inflammatory factor-1 is a marker of activated human vascular smooth muscle cells and arterial injury. Arterioscler Thromb Vasc Biol 2000, 20(7):1737-1744.
10. Sommerville L.J., Kelemen S.E., Autieri M.V. Increased smooth muscle cell activation and neointima formation in response to injury in AIF-1 transgenic mice. Arterioscler Thromb Vasc Biol 2008, 28(1):47-53.
11. Sommerville L.J., Xing C., Kelemen S.E., Eguchi S., Autieri M.V. Inhibition of allograft inflammatory factor-1 expression reduces development of neointimal hyperplasia and p38 kinase activity. Cardiovasc Res 2009, 81(1):206-215.
12. Autieri M.V., Kelemen S., Thomas B.A., et al. Allograft inflammatory factor-1 expression correlates with cardiac rejection and development of cardiac allograft vasculopathy. Circulation 2002, 106(17):2218-2223.
13. Seo D., Wang T., Dressman H., et al. Gene expression phenotypes of atherosclerosis. Arterioscler Thromb Vasc Biol 2004, 24(10):1922-1927.
14. -/- mice. Int J Mol Med 2008, 21(2):181-187.
15. Tian Y., Kelemen S.E., Autieri M.V. Inhibition of AIF-1 expression by constitutive siRNA expression reduces macrophage migration, proliferation, and signal transduction initiated by atherogenic stimuli. Am J Physiol Cell Physiol 2006, 290(4):C1083-C1091.
16. Arvanitis D.A., Flouris G.A., Spandidos D.A. Genomic rearrangements on VCAM1, SELE, APEG1 and AIF1 loci in atherosclerosis. J Cell Mol Med 2005, 9(1):153-159.
17. Wamhoff B.R., Hoofnagle M.H., Burns A., et al. A G/C element mediates repression of the SM22alpha promoter within phenotypically modulated smooth muscle cells in experimental atherosclerosis. Circ Res 2004, 95:981-988.
18. Zhang C., Zheng H., Yu Q., et al. A practical method for quantifying atherosclerotic lesions in rabbits. J Comp Pathol 2010, 142:122-128.
19. Cuneo A.A., Herrick D., Autieri M.V. Il-19 reduces VSMC activation by regulation of mRNA regulatory factor HuR and reduction of mRNA stability. J Mol Cell Cardiol 2010, 49(4):647-654.
20. Osto E., Kouroedov A., Mocharla P., et al. Inhibition of protein kinase Cbeta prevents foam cell formation by reducing scavenger receptor A expression in human macrophages. Circulation 2008, 118(21):2174-2182.
21. Brand K., Page S., Walli A.K., Neumeier D., Baeuerle P.A. Role of nuclear factor-kappa B in atherogenesis. Exp Physiol 1997, 82(2):297-304.
22. Murphy J.E., Tedbury P.R., Homer-Vanniasinkam S., Walker J.H., Ponnambalam S. Biochemistry and cell biology of mammalian scavenger receptors. Atherosclerosis 2005, 182(September (1)):1-15.
23. Daugherty A., Rateri D.L. Development of experimental designs for atherosclerosis studies in mice. Methods 2005, 36(2):129-138.
24. Tangirala R.K., Rubin E.M., Palinski W. Quantification of atherosclerosis in murine models: correlation between lesions in the aortic origin and in the differences in the extent of lesions between sexes in LDL receptor-deficient and apolipoprotein E-deficient mice. J Lipid Res 1995, 36(11):2320-2328.
25. Kenagy R.D., Hart C.E., Stetler-Stevenson W.G., Clowes A.W. Primate smooth muscle cell migration from aortic explants is mediated by endogenous platelet-derived growth factor and basic fibroblast growth factor acting through matrix metalloproteinases 2 and 9. Circulation 1997, 96:3555-3560.
26. Liu S., Tan W.Y., Chen Q.R., et al. Daintain/AIF-1 promotes breast cancer proliferation via activation of the NF-kappaB/cyclin D1 pathway and facilitates tumor growth. Cancer Sci 2008, 99(5):952-957.
27. Autieri M.V., Carbone C.M. Overexpression of allograft inflammatory factor-1 promotes proliferation of vascular smooth muscle cells by cell cycle deregulation. Arterioscler Thromb Vasc Biol 2001, 21(9):1421-1426.
28. Autieri M.V., Kelemen S.E., Wendt K.W. AIF-1 is an actin-polymerizing and Rac1-activating protein that promotes vascular smooth muscle cell migration. Circ Res 2003, 92(10):1107-1114.
29. Mehta J.L., Sanada N., Hu C.P., et al. Deletion of LOX-1 reduces atherogenesis in LDLR knockout mice fed high cholesterol diet. Circ Res 2007, 100(11):1634-1642.
30. Mandosi E., Fallarino M., Gatti A., et al. Atorvastatin downregulates monocyte CD36 expression, nuclear NFkappaB and TNFalpha levels in type 2 diabetes. J Atheroscler Thromb 2010, 17(6):539-545.